Harvest One Reports Favorable Phase 2 Clinical Trials Using Satipharm Capsules

Visit the Harvest One Cannabis Investor Dashboard and stay up to date with data-driven, fact based due diligence for active traders and investors.

Harvest One Cannabis Inc. – Favourable Results from Phase 2 Clinical Trials using Satipharm Capsules

VANCOUVER, Feb. 1, 2018 /CNW/ – Harvest One Cannabis Inc. (TSXV: HVT) (“Harvest One” or the “Company”) through its wholly-owned subsidiary Satipharm AG (“Satipharm”) is pleased to announce its proprietary capsules were used in a Phase 2 Clinical Trials undertaken by Israeli-based PhytoTech Therapeutics Ltd (“PTL”) a wholly owned subsidiary of MMJ PhytoTech limited (“MMJ”). The Phase 2 trial is an open-label, single-centre clinical study to evaluate the safety, tolerability

... read more at: https://www.newcannabisventures.com/harvest-one-reports-favorable-phase-2-clinical-trials-using-satipharm-capsules/